ABSTRACT Ipratropium bromide is a bronchodilator whose effect has been compared with beta agonists but not with theophylline. Twelve asthmatics were given four two-week courses of the different combinations of ipratropium (40 ,ug in two puffs), theophylline capsules, and their corresponding placebos in a random, double-blind fashion. There was a significant increase in FEV, and MMFR 60 minutes after theophylline was administered (p<0O05) when measured after one and two weeks of therapy. FEV, and MMFR were significantly increased (p<0O05) 30 and 60 minutes after ipratropium inhalation and this increase was significantly greater when the patient had also been taking theophylline compared with placebo capsules (p<005). There was no toxicity associated with this combination. The synergism demonstrated may be related to the time sequence of drug administration, mechanical or cellular factors.
its use has been free of the undesirable systemic effects of atropine.
The interaction, and relative efficacy of anticholinergic medication and beta sympathetic agonists such as isoprenaline, fenoterol, and salbutamol, have been studied,6"-0 but similar studies with ipratropium and oral theophylline have not been done. The purpose of the present study was to assess the efficacy of ipratropium and to establish whether there was any synergism with oral theophylline.
Methods
Individuals participating in this study had asthma as defined by the American Thoracic Society." All subjects had evidence of reversible airway obstruc-tion as manifest by either a 20% or greater increase in forced expiratory volume in one second (FEV1) within 30 minutes of inhalation of 200 ,ug of salbutamol, or a day-to-day variation in FEV, in excess of 15%.
Informed consent was obtained from all subjects, and this study was approved by the hospital ethics committee.
One of 12 subjects currently smoked one to five cigarettes daily, while six were ex-smokers (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) pack-years, mean 17+4-1-7 pack-years), and five had never smoked. No subject had a history of chronic bronchitis, cardiac, renal, or hepatic disease.
For the purpose of this study an optimum theophylline dose for a particular patient was defined as that quantity which produced the highest serum theophylline concentration in the desired therapeutic range (10-20 ,ug/ml) one hour after ingestion, without producing side-effects. 10 hours, and smoking was prohibited for two hours, before and until termination of the testing.
Blood was drawn for determination of serum theophylline concentration one hour after ingestion of the test capsule.
Each subject kept a diary describing daily respiratory symptoms, benefits, and side-effects of test medications, and need for other bronchodilators. Subjective parameters were recorded in the diary and scored as follows: overall benefit (better=+1, same=0, worse=-1), amount of wheezing (less= + 1, same=0, more=-1), shortness of breath, and chest tightness (each on a scale of 1-10, 10 being best, 1 being worst).
An analysis of variance procedure appropriate to the 22 factorial design was used to assess the overall efficacy of ipratropium, the overall efficacy of theophylline, and any synergism between these two treatments. The overall ipratropium effect was assessed by comparing the mean change in FEVY (or MMFR) when the patient was on ipratropium (with or without theophylline) with the corresponding change when the patient was on placebo inhaler. The overall theophylline effect was calculated in a similar manner.
If ipratropium and theophylline merely act in an additive fashion the effect of ipratropium would be expected to be the same in the presence of theophylline or placebo capsules. Synergism between these agents was therefore sought by determining whether the effect of ipratropium was significantly greater in the presence of theophylline versus placebo capsules.14
Results
Seven males and five female asthmatic subjects aged 21-54 years (mean 34+2X4 yr) completed the study. Three other individuals withdrew from the study before completion, and were excluded from statistical analysis. The three subjects who withdrew from the study did so for the following reasons. One completed the first treatment period (theophylline and placebo aerosol) but claimed the capsules made her "high". Another subject completed one week of theophylline and placebo aerosol, but was too ill to abstain from bronchodilators for the required 10-hour period before testing. The third subject completed two weeks of placebo capsules, and placebo aerosol but discontinued because of the inconvenience of repeated testing.
The mean optimum theophylline dose (+SE) was 1183+96 mg daily of the choline salt (range 800-2000 mg). Serum (1)
The effect of theophylline, which is a combined benefit of both chronic and acute administration, can be assessed by comparing the "baseline" values with the pre-treatment values. On this basis, there was a significant theophylline effect with a mean increase in FEV1 of 0-33-+0-16 litres (p<0 05) and a mean increase in MMFR of 0-23=40.12 litres/s (p<0 05). There was no demonstrable effect of chronic administration of ipratropium, similarly assessed by comparing pretreatment to baseline values in regimens in which the active inhaler had been administered.
The overall benefit of acute administration of ipratropium, as calculated by determining the ipratropium effect, was assessed by comparing the mean increases at 30 minutes and 60 minutes after inhalation with the corresponding baseline values. These mean increases are summarised in table 3. The efficacy of ipratropium is reflected in a relative mean increase in FEVy of 0-20±0-05, and 0-19-+0.06 litres at 30 and 60 minutes respectively (p<0-001). The corresponding increases in MMFR 
